Keyword: monoclonal antibody
Scientists are adding antigenic epitopes to an old class of antibiotic to trigger an immune response against Gram-negative bacteria.
GlaxoSmithKline will pay up to £175 million ($230 million) to gain global, exclusive rights to a Phase I monoclonal antibody to treat severe asthma from Johnson & Johnson’s Janssen.
InflaRx has raised $34 million in a Series C to at least get it through Phase II testing for its lead candidate, as well as to expand its preclinical pipeline.
An FDA advisory committee recommended that the agency approve Valeant’s brodalumab to treat moderate-to-severe plaque psoriasis.
Takeda becomes the latest in a long list of Big Pharma drugmakers to buy into Adimab’s antibody platform to help it discover and develop a range of new drugs.